ArticleOrphanet journal of rare diseases2026
The economic burden of amyotrophic lateral sclerosis for patients and families: a survey on out-of-pocket expenses and income loss in France.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionMost published economic studies about the burden of amyotrophic lateral sclerosis (ALS) have measured direct and indirect costs but did not consider the perspective of patients and families. MATERIALS AND
methodsThe French ALS patient association, ARSLA, contacted 15 ALS reference centers to recruit a random sample of ALS patients stratified by age and severity accepting to participate in a structured interview survey. The objective was to document the out-of-pocket (OOP) expenses associated with ALS for patients and families in 2024.
resultsFifty patients with a mean age 61.5 years (SD 12) participated in the survey. The average time since diagnosis was 28.9 months (SD 26.8). Most patients had disabling motor impairment, half of them (n = 26, 52%) affected 4 limbs, 27 (54%) required noninvasive respiratory support and 11 (22%) nutritional support. A proportion of 48% of patients or caregivers reported Out-of-Pocket (OOP) expenses for mobility equipment, 50% for home modifications, 40% for vehicle adaptations, and 54% for paying for paid caregivers. The mean annual OOP expenses was €7,764 (SD 9,776) in total of which home adaptations averaged €3,074 (SD 6,583), personal vehicle adaptation €2,774 (SD 5,239) and paid caregivers €1,279 (SD 3,351). The factors statistically significant for higher overall OOP expenses were the duration of ALS since diagnostic (p = 0.026) and use of paid caregivers (p = 0.005). The support of family caregivers was almost systematic (88%), involving spouses (95.5%), children (22.7%) and relatives (13.6%). The mean annual loss of family income associated with professional change of patients and family caregivers was €7,633. When added to the OOP, the mean total annual economic burden was €15,397.
conclusionDespite the full coverage of all ALS-related health expenditures within the French healthcare system and additional associated financial support, it remains a substantial economic burden for patients and families to manage this condition. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.